

## GLP-1(7-37) acetate

<b>Cat. No.:</b>	HY-P0055A
<b>CAS No.:</b>	1450806-98-0
<b>Molecular Formula:</b>	C <sub>153</sub> H <sub>232</sub> N <sub>40</sub> O <sub>49</sub>
<b>Molecular Weight:</b>	3415.72
<b>Sequence:</b>	His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly
<b>Sequence Shortening:</b>	HAEGTFTSDVSSYLEGQAAKEFIAWLKGRG
<b>Target:</b>	Glucagon Receptor
<b>Pathway:</b>	GPCR/G Protein
<b>Storage:</b>	Protect from light Powder    -80°C    2 years -20°C    1 year

\* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

### BIOLOGICAL ACTIVITY

Description	GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion <sup>[1]</sup> .	
In Vivo	GLP-1(7-37) (0.5, 5 or 50 pmol/min/kg) infused during the second hour of a 2-hour 11-mM hyperglycemic clamp produces a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion in rats <sup>[2]</sup> .	
	Infusion of GLP-1(7-37) (5 pmol/min/kg) from 1 hour through 7 hours produces a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle in rats with maintained glucose concentration at 11 mM <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	<b>Animal Model:</b>	Male Sprague-Dawley rats weighing 300 to 350 g with glucose IV at a variable rate for 7 hours to maintain plasma glucose concentration at 11 mM <sup>[2]</sup> .
	<b>Dosage:</b>	5 pmol/min/kg.
	<b>Administration:</b>	IV from 1 hour through 7 hours <sup>[2]</sup> .
	<b>Result:</b>	Produced a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle.
	<b>Animal Model:</b>	Male Sprague-Dawley rats weighing 300 to 350 g with maintained plasma glucose concentration at 11 mM <sup>[2]</sup> .
	<b>Dosage:</b>	0.5, 5 or 50 pmol/min/kg.
	<b>Administration:</b>	IV during the second hour of a 2-hour 11-mmol/L hyperglycemic clamp.
	<b>Result:</b>	Produced a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion.

---

## CUSTOMER VALIDATION

- Patent. US20200283424A1.
- Patent. US20200283424A1.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Sarrauste de Menthiere, C. et al. Structural requirements of the N-terminal region of GLP-1-[7-37]-NH<sub>2</sub> for receptor interaction and cAMP production. European journal of medicinal chemistry 39, 473-480, doi:10.1016/j.ejmech.2004.02.002 (2004).
- [2]. Hargrove DM, et al. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism. 1995 Sep;44(9):1231-7.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

**India Contact:**

Life Technologies (India) Pvt. Ltd.

306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi – 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444

Email: [customerservice@lifetechindia.com](mailto:customerservice@lifetechindia.com) Website: [www.lifetechindia.com](http://www.lifetechindia.com)